Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Sanofi Genzyme Recognizes Rare Disease Day 2016 with Program of Events around the World

Business Wire February 29, 2016

Sanofi Genzyme Recognises 2016 International Rare Disease Day with Premiere of Expression of Hope Film

PR Newswire February 29, 2016

Sanofi Genzyme Leadership in Rare Diseases Highlighted at WORLDSymposium 2016

Business Wire February 26, 2016

Market Sentiments Captured by Price Data - New Research on Sanofi, Cablevision Systems, Coca-Cola Enterprises and Arthur J Gallagher & Co

Accesswire February 25, 2016

High-Dose Influenza Vaccine Recognized as a New Option with Demonstrated Superior Efficacy* for Adults 65 Years and Older

Canada NewsWire February 24, 2016

Sanofi US to Return Auvi-Q® (epinephrine injection, USP) Rights to kaléo

PR Newswire February 23, 2016

Sanofi - Full Year 2015 Results

PR Newswire February 9, 2016

Moderate Improvements in Blood Glucose Levels Could Deliver Significant Benefits for People With Diabetes in the UK and the NHS

PR Newswire February 3, 2016

Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA

PR Newswire January 8, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MannKind Corp. (MNKD)

PR Newswire January 7, 2016

Sanofi Genzyme Announces Recipients of Patient Advocacy Leadership (PAL) Awards

Business Wire January 6, 2016

Global Genomics Group (G3) Partners with Sanofi to Identify New Signaling Pathways in Atherosclerotic Cardiovascular Diseases

PR Newswire January 5, 2016

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

PR Newswire December 11, 2015

Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

PR Newswire December 11, 2015

Sanofi Launches New Priftin® (Rifapentine) Packaging

PR Newswire December 1, 2015

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

PR Newswire November 24, 2015

Perceptions of Counterfeit Medicines: Only 12% of Americans Feel They Have Enough Information

PR Newswire November 20, 2015

Sanofi and Regeneron Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015

PR Newswire November 10, 2015

Regeneron and Sanofi Announce New Praluent® (alirocumab) Injection Analyses Presented at AHA Scientific Sessions 2015

PR Newswire November 10, 2015

Sanofi and Regeneron Present Results from Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting

PR Newswire November 8, 2015